OncoMatch/Clinical Trials/NCT06492954
Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma
Is NCT06492954 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Atezolizumab for osteosarcoma.
Treatment: Atezolizumab — This study aims to determine the safety and tolerability of combined Atezolizumab, stereotactic body radiation therapy (SBRT), and surgical resection of pulmonary metastases in patients with pulmonary recurrence of osteosarcoma
Check if I qualifyExtracted eligibility criteria
Cancer type
Osteosarcoma
Disease stage
Metastatic disease required
Participants must be in first or greater relapse of osteosarcoma; Recurrence must be limited to the lung but can be unilateral or bilateral
Performance status
LANSKY/KARNOFSKY/ECOG 60–2
Lansky (≤ 16 years) or Karnofsky (> 16 years) score of ≥ 60, or ECOG performance score of ≤ 2
Prior therapy
Cannot have received: lung radiation
Prior lung radiation
Cannot have received: allogeneic stem cell transplant
prior allogeneic stem cell transplant
Cannot have received: solid organ transplant
prior solid organ transplant
Lab requirements
Blood counts
Peripheral ANC ≥ 750/mm3, Platelet count ≥ 50,000/mm3, transfusion independent (no platelet transfusions for at least 7 days before enrollment)
Kidney function
Creatinine clearance or radioisotope GFR ≥ 70 ml/min/1.73 m2
Liver function
Total bilirubin ≤ 1.5 x ULN for age, ALT (SGPT) ≤ 3 x ULN (ULN for ALT is 45 U/L)
Cardiac function
QTc ≤ 480 msec, Shortening fraction ≥ 27% by echocardiogram or ejection fraction ≥ 50% by gated radionuclide study or echocardiogram
Adequate Bone Marrow Function... Adequate Renal Function... Adequate Liver Function... Adequate Cardiac Function...
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Chilldren's Healthcare of Atlanta · Atlanta, Georgia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify